BHV-1200 / Biohaven - LARVOL DELTA

Biohaven’s BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19 (PRNewswire) - "Biohaven Pharmaceutical Holding Company Ltd....announced that a hyperimmune globulin mimic (HGM) developed with Biohaven's proprietary MATE platform has demonstrated functional binding and neutralization of the SARS-CoV-2 virus, including the strains known as the 'English' and 'South African' variants (also known as B.1.1.7 and B.1.351, respectively)....BHV-1200 substantially reduced viral entry into cells. Accelerated development of the COVID-19 MATE program has been supported by the Bill and Melinda Gates Foundation."

Preclinical • Infectious Disease • Novel Coronavirus Disease

Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients (GlobeNewswire) - "Kleo Pharmaceuticals...announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation to advance the development of Kleo’s COVID-19 treatment leveraging its MATE™ (Monoclonal Antibody Therapy Enhancers) technology platform to combat the SARS-CoV-2 virus....'This non-dilutive funding allows us to rapidly advance clinical candidate identification efforts with the goal of entering the clinic in early 2021'....Kleo has also recently established collaborations with South Korea-based Green Cross LabCell (GCLC)...to explore and develop COVID-19 therapies..."

Grant • Infectious Disease • Novel Coronavirus Disease